clinical trial · NCT06090539
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Bristol-Myers Squibb·phase2·recruiting·n = 308
Relapsed/Refractory Non-Hodgkin LymphomaBMS-986458RituximabGlofitamab/ObinutuzumabMosunetuzumab
brief summary
The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary biological and clinical activity of BMS-986458, a bifunctional cereblon-dependent ligand-directed degrader of B-cell lymphoma 6 (BCL6), as a single agent and in combination with anti-lymphoma agents in participants with relapsed/refractory non-Hodgkin Lymphoma.
started
Dec 29, 2023
primary completion
Oct 28, 2027
completion
Oct 28, 2028
last updated
Apr 14, 2026
official title
A Phase 1/2, Multi-Center, Open-Label, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BMS-986458, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed/Refractory Non-Hodgkin Lymphomas (R/R NHL)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol